Sign inJoin waitlistJoin the waitlist

Frances Valdes

Associate Professor of Clinical Medicine, Medical Oncology · University of Miami/Jackson Health System

Credentials: · · · ·

History

University of Miami/Jackson Health System
Present

Hematology and Medical Oncology
2001–2004
University of California-San Francisco
1998–2001
Johns Hopkins Univ Sch of Med
1994–1998

Research

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Clinical Cancer Research · 2024 · 44 citations
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
npj Precision Oncology · 2023 · 41 citations
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1
Anti-Cancer Drugs · 2006 · Last of 3 authors · 29 citations

Warren Chow
3 papers
Charles Geyer
2 papers
EH
Erika Hamilton
2 papers
Judy Garber
2 papers
MM
Monica Mita
2 papers
Priya Rastogi
2 papers
Priyanka Sharma
2 papers
Sara Hurvitz
2 papers
SV
Shamsuddin Virani
2 papers
Susan Domchek
2 papers
Antoinette Tan
1 paper
AW
Antonio Wolff
1 paper

Clinical trials

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
Principal investigator · Active not recruiting · Phase 2
University of Miami
2023–2029
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Eikon Therapeutics
2023–2027